Brief: Acucort Is Exempted From The Application Fee By The U.S. Food And Drug Administration
AcuCort AB ACUC.TE :
* ACUCORT IS EXEMPTED FROM THE APPLICATION FEE BY THE U.S.
FOOD
AND DRUG ADMINISTRATION
* ACUCORT AB - FDA GRANTS CO'S WAIVER REQUEST UNDER SMALL
BUSINESS
WAIVER PROVISION REGARDING APPLICATION FEE FOR NEW DRUG
APPLICATION OF ISICORT
* ACUCORT AB - EXEMPTED FROM PAYING APPLICATION FEE OF $1.6
MILLION PROVIDED NEW DRUG APPLICATION OF ISICORT IS SUBMITTED NO
LATER THAN LAST DAY OF FEB 2023
Source text for Eikon: ID:nPn5hBTPja
Further company coverage: ACUC.TE
Recent news on AcuCort AB
See all newsBrief: Acucort Plans To Apply For U.S. Market Approval For Zeqmelit In 2026
Brief: AcuCort Signs Its First Commercial Agreement For Zeqmelit
Brief: Acucort AB Acucort Receives Marketing Authorization For Drug Zeqmelit By Norwegian Medicines Agency
Brief: Acucort Receives Marketing Authorization For The Drug Zeqmelit By The Danish Medicines Agency
Brief: AcuCort Is Granted Sme Status By The European Medicines Agency, EMA